Although NF1 is a major regulator of RAS‐MAPK pathway, only few clinical studies have described the pattern of NF1 somatic mutations in lung adenocarcinoma.5, 13, 14 Using a targeted next generation sequencing (NGS) approach, we analyzed a large cohort of resected lung adenocarcinomas to characterize NF1 mutations, and we evaluated the molecular and clinical specificities of NF1‐mutated lung cancers. The gene discussed is NF1; the disease is lung carcinoma.